BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 18482778)

  • 1. An HIV-1 215V mutant shows increased phenotypic resistance to d4T.
    Pernas M; López-Galíndez C
    Virus Res; 2008 Aug; 135(2):340-4. PubMed ID: 18482778
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transmitted human immunodeficiency virus type 1 carrying the D67N or K219Q/E mutation evolves rapidly to zidovudine resistance in vitro and shows a high replicative fitness in the presence of zidovudine.
    García-Lerma JG; MacInnes H; Bennett D; Weinstock H; Heneine W
    J Virol; 2004 Jul; 78(14):7545-52. PubMed ID: 15220429
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thymidine analog and multinucleoside resistance mutations are associated with decreased phenotypic susceptibility to stavudine in HIV type 1 isolated from zidovudine-naive patients experiencing viremia on stavudine-containing regimens.
    Ross L; Scarsella A; Raffanti S; Henry K; Becker S; Fisher R; Liao Q; Hirani A; Graham N; St Clair M; Hernandez J;
    AIDS Res Hum Retroviruses; 2001 Aug; 17(12):1107-15. PubMed ID: 11522180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of the Delta67 complex of mutations in human immunodeficiency virus type 1 reverse transcriptase on nucleoside analog excision.
    Boyer PL; Imamichi T; Sarafianos SG; Arnold E; Hughes SH
    J Virol; 2004 Sep; 78(18):9987-97. PubMed ID: 15331732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Natural resistance of human immunodeficiency virus type 2 to zidovudine.
    Reid P; MacInnes H; Cong ME; Heneine W; García-Lerma JG
    Virology; 2005 Jun; 336(2):251-64. PubMed ID: 15892966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NNRTI-selected mutations at codon 190 of human immunodeficiency virus type 1 reverse transcriptase decrease susceptibility to stavudine and zidovudine.
    Paolucci S; Baldanti F; Campanini G; Cancio R; Belfiore A; Maga G; Gerna G
    Antiviral Res; 2007 Nov; 76(2):99-103. PubMed ID: 17640745
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evolution of AZT resistance in HIV-1: the 41-70 intermediate that is not observed in vivo has a replication defect.
    Jeeninga RE; Keulen W; Boucher C; Sanders RW; Berkhout B
    Virology; 2001 May; 283(2):294-305. PubMed ID: 11336554
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel genetic pathway of human immunodeficiency virus type 1 resistance to stavudine mediated by the K65R mutation.
    García-Lerma JG; MacInnes H; Bennett D; Reid P; Nidtha S; Weinstock H; Kaplan JE; Heneine W
    J Virol; 2003 May; 77(10):5685-93. PubMed ID: 12719561
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro selection of mutations in human immunodeficiency virus type 1 reverse transcriptase that confer resistance to capravirine, a novel nonnucleoside reverse transcriptase inhibitor.
    Sato A; Hammond J; Alexander TN; Graham JP; Binford S; Sugita K; Sugimoto H; Fujiwara T; Patick AK
    Antiviral Res; 2006 Jun; 70(2):66-74. PubMed ID: 16472877
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relative replication fitness of multi-nucleoside analogue-resistant HIV-1 strains bearing a dipeptide insertion in the fingers subdomain of the reverse transcriptase and mutations at codons 67 and 215.
    Prado JG; Franco S; Matamoros T; Ruiz L; Clotet B; Menéndez-Arias L; Martínez MA; Martinez-Picado J
    Virology; 2004 Aug; 326(1):103-12. PubMed ID: 15262499
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suppression of replication of multidrug-resistant HIV type 1 variants by combinations of thymidylate synthase inhibitors with zidovudine or stavudine.
    Gao WY; Johns DG; Tanaka M; Mitsuya H
    Mol Pharmacol; 1999 Mar; 55(3):535-40. PubMed ID: 10051538
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro study of resistance-associated genotypic mutations to nucleoside analogs.
    Gashnikova N; Plyasunova O; Kiseleva Y; Fedyuk N; Pokrovsky A
    Nucleosides Nucleotides Nucleic Acids; 2003; 22(5-8):991-4. PubMed ID: 14565328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanistic basis of zidovudine hypersusceptibility and lamivudine resistance conferred by the deletion of codon 69 in the HIV-1 reverse transcriptase coding region.
    Kisic M; Mendieta J; Puertas MC; Parera M; Martínez MA; Martinez-Picado J; Menéndez-Arias L
    J Mol Biol; 2008 Oct; 382(2):327-41. PubMed ID: 18662701
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutational patterns associated with the 69 insertion complex in multi-drug-resistant HIV-1 reverse transcriptase that confer increased excision activity and high-level resistance to zidovudine.
    Cases-González CE; Franco S; Martínez MA; Menéndez-Arias L
    J Mol Biol; 2007 Jan; 365(2):298-309. PubMed ID: 17070543
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Broad nucleoside-analogue resistance implications for human immunodeficiency virus type 1 reverse-transcriptase mutations at codons 44 and 118.
    Romano L; Venturi G; Bloor S; Harrigan R; Larder BA; Major JC; Zazzi M
    J Infect Dis; 2002 Apr; 185(7):898-904. PubMed ID: 11920313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence, genotypic associations and phenotypic characterization of K65R, L74V and other HIV-1 RT resistance mutations in a commercial database.
    McColl DJ; Chappey C; Parkin NT; Miller MD
    Antivir Ther; 2008; 13(2):189-97. PubMed ID: 18505170
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A new strategy based on recombinant viruses as a tool for assessing drug susceptibility of human immunodeficiency virus type 1.
    Garcia-Perez J; Sanchez-Palomino S; Perez-Olmeda M; Fernandez B; Alcami J
    J Med Virol; 2007 Feb; 79(2):127-37. PubMed ID: 17177310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel patterns of nevirapine resistance-associated mutations of human immunodeficiency virus type 1 in treatment-naïve patients.
    Hachiya A; Gatanaga H; Kodama E; Ikeuchi M; Matsuoka M; Harada S; Mitsuya H; Kimura S; Oka S
    Virology; 2004 Oct; 327(2):215-24. PubMed ID: 15351209
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primary drug resistance in antiretroviral-naïve injection drug users.
    Tossonian HK; Raffa JD; Grebely J; Viljoen M; Mead A; Khara M; McLean M; Krishnamurthy A; DeVlaming S; Conway B
    Int J Infect Dis; 2009 Sep; 13(5):577-83. PubMed ID: 19111493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Susceptibility of human T cell leukemia virus type 1 to reverse-transcriptase inhibitors: evidence for resistance to lamivudine.
    García-Lerma JG; Nidtha S; Heneine W
    J Infect Dis; 2001 Aug; 184(4):507-10. PubMed ID: 11471110
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.